Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

OBJECTIVES: To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs). METHODS: Adults with active AS who met modified New York crit...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Baraliakos, Xenofon, Sieper, Joachim, Deodhar, Atul, Inman, Robert D, Kameda, Hideto, Zeng, Xiaofeng, Sui, Yunxia, Bu, Xianwei, Pangan, Aileen L, Wung, Peter, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606523/
https://www.ncbi.nlm.nih.gov/pubmed/35788492
http://dx.doi.org/10.1136/ard-2022-222608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606523/
https://www.ncbi.nlm.nih.gov/pubmed/35788492
http://dx.doi.org/10.1136/ard-2022-222608

Ejemplares similares